National Bank of Canada FI Acquires 56,797 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

National Bank of Canada FI lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 27.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 263,462 shares of the medical equipment provider's stock after acquiring an additional 56,797 shares during the period. National Bank of Canada FI owned approximately 0.13% of Zimmer Biomet worth $27,830,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ZBH. Franklin Resources Inc. grew its stake in Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Summit Financial LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $204,000. Alliancebernstein L.P. raised its stake in Zimmer Biomet by 7.5% during the 4th quarter. Alliancebernstein L.P. now owns 326,802 shares of the medical equipment provider's stock valued at $34,520,000 after acquiring an additional 22,784 shares in the last quarter. Hazlett Burt & Watson Inc. lifted its holdings in Zimmer Biomet by 23.7% in the fourth quarter. Hazlett Burt & Watson Inc. now owns 815 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 156 shares during the period. Finally, Bcwm LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $1,982,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Down 4.6 %

ZBH traded down $5.20 during mid-day trading on Friday, reaching $107.46. 3,852,949 shares of the stock were exchanged, compared to its average volume of 1,587,609. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a 50 day moving average price of $107.32 and a two-hundred day moving average price of $107.21. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $129.50. The stock has a market capitalization of $21.39 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business earned $2.20 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ZBH shares. Raymond James reduced their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $124.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.70% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.